# Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments

Clene (NASDAQ: CLNN) has announced a $10 million debt facility with three affiliated entities, set to close by December 20, 2024. The 18-month secured, partially convertible note carries a 12% fixed interest rate, with an interest-only period for the first year. Sixty-five percent of the note is convertible into common stock at $5.67 per share, a 130% premium over the stock’s signing day closing price. Proceeds will support Clene’s development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval. The company also aims to repay its prior $7.9 million Loan Agreement with Avenue Venture Opportunities Fund.

 To view the full press release, visit https://ibn.fm/PYUp3

 About Clene Inc.

 Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/clene-nasdaq-clnn-secures-10m-debt-facility-to-advance-neurodegenerative-disease-treatments/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/clene-announces-10-million-debt-facility-for-cnm-au8-treatment-development/12913513232b24cb8cdaf376be88e5cd) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1hhypop/clene_announces_10_million_debt_facility_for/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2412/19/yawnyJXd.webp)